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Abstract
Background: Activation Induced cytidine Deaminase (AID) targets the immunoglobulin genes of activated B cells,
where it converts cytidine to uracil to induce mutagenesis and recombination. While essential for immunoglobulin
gene diversification, AID misregulation can result in genomic instability and oncogenic transformation. This is
classically illustrated in Burkitt’s lymphoma, which is characterized by AID-induced mutation and reciprocal
translocation of the c-MYC oncogene with the IgH loci. Originally thought to be B cell-specific, AID now appears to
be misexpressed in several epithelial cancers, raising the specter that AID may also participate in non-B cell
carcinogenesis.
Methods: The mutagenic potential of AID argues for the existence of cellular regulators capable of repressing
inappropriate AID expression. MicroRNAs (miRs) have this capacity, and we have examined the publically available
human AID EST dataset for miR complementarities to the human AID 3’UTR. In this work, we have evaluated the
capacity of two candidate miRs to repress human AID expression in MCF-7 breast carcinoma cells.
Results: We have discovered moderate miR-155 and pronounced miR-93 complementary target sites encoded
within the human AID mRNA. Luciferase reporter assays indicate that both miR-93 and miR-155 can interact with
the 3’UTR of AID to block expression. In addition, over-expression of either miR in MCF-7 cells reduces endogenous
AID protein, but not mRNA, levels. Similarly indicative of AID translational regulation, depletion of either miR in
MCF-7 cells increases AID protein levels without concurrent increases in AID mRNA.
Conclusions: Together, our findings demonstrate that miR-93 and miR-155 constitutively suppress AID translation
in MCF-7 cells, suggesting widespread roles for these miRs in preventing genome cytidine deaminations,
mutagenesis, and oncogenic transformation. In addition, our characterization of an obscured miR-93 target site
located within the AID 3’UTR supports the recent suggestion that many miR regulations have been overlooked due
to the prevalence of truncated 3’UTR annotations.
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Background
In antigen activated B cells the Activation Induced cyti-
dine Deaminase (AID) protein is required for initiating
mutagenesis and recombination of the immunoglobulin
(Ig) genes to promote immunity. AID is a cytidine dea-
minase that converts single-stranded genomic cytidine
into uracil, and its activity is pronounced at the Ig vari-
able (V) and switch (S) regions [1-5]. While sponta-
neously generated uracil in the genome is faithfully
corrected as a part of normal DNA repair [6], AID-
induced uracils at the Ig loci are mutagenically resolved
by multiple DNA repair factors [4,7]. Although AID tar-
gets the Ig loci in activated B cells, activity at other
genomic sites has the potential to create oncogenic
DNA damage. Indeed, transcribed genes across the gen-
ome have now been found to undergo AID deamination
(reviewed by [8,9]), and recently, deep sequencing of
AID-ChIPed template revealed broad AID-associations
with expressed loci [10]. In addition, AID-dependent
DNA breaks were recently identified within multiple
types of repetitive elements [11] suggesting a broad abil-
ity for AID to target genomic regions harboring single-
stranded character.
* Correspondence: elarson@ilstu.edu
School of Biological Sciences, Illinois State University, Normal, IL 61790-4120,
USA
Borchert et al. BMC Cancer 2011, 11:347
http://www.biomedcentral.com/1471-2407/11/347
© 2011 Borchert et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.AID misexpression results in DNA damage that pro-
motes cancer [11-16]. In lymphoid cells improper AID
expression has been connected with mutations at c-
MYC, PIM1, RhoH and PAX5 oncogenes, promoting dif-
fuse large B cell lymphoma [17]. Similarly, Burkitt’sl y m -
phoma is characterized by AID-induced mutation and a
reciprocal translocation between the c-MYC proto-onco-
gene and the IgH loci [9,18-20]. While AID expression
was initially thought to be B cell-specific, recent evi-
dence indicates AID may promote the development of
various non-lymphoid oncologies. In gastric cancer, the
upregulation of AID leads to point mutations and copy
number alterations of CDKN2A and CDKN2B tumor
suppressor genes [21]. In the same manner, AID misex-
pression in human colonic cells increases the mutation
rate of TP53 by ~10-fold [22]. In addition, AID is
expressed at various levels in ~1/3 of primary lung can-
cers [23] and in numerous breast cancer cell lines [24]
(where AID misexpression may be due in part to obser-
vations that estrogen is capable of inducing AID expres-
sion > 20 fold [25]). Since errant AID activity can
introduce significant genomic damage, the maintenance
of genome stability outside of the activated B cell envir-
onment likely depends upon multiple molecular AID
restraints.
Recent evidence suggests that one level of AID regula-
tion comes from microRNAs (miRs). These short, ~20
nt, noncoding RNAs can regulate networks of genes and
function by repressing translation or directing mRNA
destruction through partial sequence complementarity
to 3’ untranslated regions (3’UTRs) of mRNAs [26,27].
MiRs are key regulators of cellular differentiation, prolif-
eration and apoptosis, and aberrant miR expression has
been associated with a myriad of human diseases,
including cancer (reviewed by [28]). A subset of miRs
typically misexpressed in malignancy (oncomiRs) can
function as oncogenes or tumor suppressors with
impacts on cellular transformation and metastasis. One
such oncomiR, miR-155, represses murine AID,a n dt h e
disruption of the miR-155 recognition site or miR-155
itself results in increased AID-induced c-MYC transloca-
tion [29] and BCL6 mutagenesis [30]. This may provide
one explanation for why disruption of miR-155 is asso-
ciated with Burkitt’s lymphoma [31] and suggests the
existence of parallel miR repressions in humans.
In order to better define the regulators of human AID
in cells other than antigen-activated B cells, we exam-
ined the 3’UTR of human AID for miR complementari-
ties. Consistent with the role of miR-155 in regulating
AID in mice [29,30], we find a moderate miR-155 site in
human AID. Surprisingly, we also find a previously
uncharacterized, yet exceptional, complementarity to
miR-93 in the AID 3’UTR. We show both of these miRs
interact with the AID 3’UTR in the cell to regulate its
translation, and that loss of either miR results in
increased AID protein levels. Based on the involvement
of AID in generating oncogenic genome mutations, our
results suggest that miR-93 and miR-155 act as dual
genome sentries to prevent errant translation of AID
mRNA.
Methods
Reagents and cell lines
Oligonucleotide sequences are detailed in Additional
File 1, Table S1. Human embryonic kidney (HEK293)
cell line was obtained from GenLantis (San Diego, CA),
Burkitt’s lymphoma (Ramos) and breast cancer (MCF-7)
cells were both purchased from the American Type Cul-
t u r eC o l l e c t i o n ,( A T C C ,M a n a s s a s ,V A ) .H E K 2 9 3a n d
MCF-7 cells were cultured in MEM (Mediatech, Hern-
don, VA) supplemented with 10% fetal bovine serum
(Hyclone, Logan, UT). Ramos cells were cultured in
RPMI (Mediatech) supplemented with 10% fetal bovine
serum (Hyclone, Logan, UT). All tissue culture media
were supplemented with 25 mg/ml streptomycin and 25
I.U. penicillin (Mediatech). Cells were cultured in a
humidified atmosphere with 5% CO2 at 37°C. For luci-
ferase assays, HEK293 s were cultured in MEM (10%
FBS and 1% PS) in 12-well plates. At 90% confluency,
cells were transfected following the Lipofectamine 2000
(Invitrogen, Carlsbad, CA) protocol. At 35 h, existing
media was replaced with 1 ml fresh media. For miR
expression assays, MCF-7 s were cultured in MEM (10%
FBS and 1% PS) in 6-well plates. At 90% confluency,
cells were transfected following the Lipofectamine 2000
(Invitrogen) protocol and harvested after 48 h. For miR
sponge assays, MCF-7 s were cultured in MEM (10%
FBS and 1% PS) in 6-well plates. At 70% confluency,
cells were transfected following the Lipofectamine 2000
(Invitrogen) protocol. At 48 h, existing media was
replaced with 2 ml fresh media and cell transfections
were repeated as initially performed. Cells were then
harvested after an additional 48 h culture.
Luciferase assays
At 36 h post transfection, cells were scraped from well
bottoms and transferred to 1.5 ml Eppendorf tubes.
Eppendorfs were centrifuged at 2000 RCF for 3 min, fol-
lowed by supernatant aspiration and cell resuspension in
300 μl of PBS. Cells were lysed by freeze thaws and deb-
ris removed by centrifuging at 3000 RCF for 3 min. 50
μl of supernatant was transferred to a 96-well MicroLite
plate (MTX Lab Systems, Vienna, VA) then firefly and
Renilla luciferase activities measured using the Dual-glo
Luciferase
® Reporter System (Promega, Madison, WI)
and a 96-well plate luminometer (Dynex, Worthing,
West Sussex, UK). RLUs were calculated as the quotient
of Renilla/firefly RLU and normalized to mock.
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MCF-7 cells (at ~1 × 10
6 cells/ml) were pelleted by cen-
trifugation, existing media removed, and cells resus-
pended in SDS lysis buffer containing protease
inhibitors and transferred to 1.5 ml Eppendorf tubes.
Proteins were electrophoresed through a 4-12% SDS-
polyacrylamide gradient gel (Invitrogen) and transferred
to immobilon-P PVDF membranes (Millipore, Teme-
cula, CA). Membranes were blocked for 1 hour in 5%
(w/v) nonfat milk in phosphate-buffered saline contain-
ing 0.05% Tween 20, washed, and incubated with pri-
mary antibody overnight at 4°C using the following
dilution: anti-AID (Santa Cruz Biotechnology, Santa
Cruz, CA, sc-25620) - 1:500 and anti-PCNA (Santa
Cruz) - 1:10000. Membranes were washed and incu-
bated with secondary Abs: HRP conjugated goat anti-
mouse and goat anti-rabbit (Invitrogen) at 1:10000 dilu-
tion. Immunoreactive bands were visualized with ECL
Plus (GE, Piscataway, NJ) and signals were detected by
using the Storm 840 PhosphorImager and IMAGE-
QUANT software (GE).
Vector construction
Unless otherwise indicated, PCR amplifications were
performed in 40 μl reactions at standard concentrations
(1.5 mM MgCl2, 0.2 mM dNTP, 1× Biolase PCR buffer,
0 . 5UT a q( B i o l i n eU S A ,I n c . ,R a n d o l p h ,M A ) ,0 . 5u M
each primer) and using standard cycling parameters (94°
C - 3 min, (94°C - 30 s, 55°C - 30 s, 72°C - 60 s) × 30
cycles, 72°C - 3 min) then cloned into Topo PCR 2.1
(Invitrogen). RT-PCRs were performed at 65°C using
MonsterScript Reverse Transcriptase (#MSTA5110, Epi-
centre, Madison, WI) and gene specific or random non-
amer primers. Resultant amplicons were cloned into
Topo PCR 2.1 and sequenced. Antisense reporter, Ctl
3’LR, was constructed by oligonucleotide primer
extension (25 cycles with 10 s extensions) with primers
containing 5’ Xho-I and 3’ Spe-I restriction enzyme sites
immediately flanking sequences perfectly complemen-
tary to mature siLacZ. Antisense reporter, AID 3’LR,
was constructed by standard PCR with primers contain-
ing 5’ Xho-I and 3’ Spe-I restriction enzyme sites. Fol-
lowing digestion, amplicons were ligated into the Renilla
luciferase 3’UTR of psiCheck2 (Promega) vector linear-
ized with Xho-I and Spe-I. The presence of an indepen-
dently transcribed firefly luciferase in these reporters
allowed normalization for transfection efficiency. Sponge
expression constructs were generated by concatameriz-
ing PCR using the primers indicated in Additional File
1, Table S1. Resulting amplicons were separated on a
1% agarose gel and a band excised from the appropriate
lane at ~400 bp. Gel extractions were cloned into Topo
PCR 2.1 and sequenced. Concatamers were next excised
from Topo PCR 2.1 and cloned into the pEGFP expres-
sion vector (Clontech, Mountain View, CA) using
BamHI and Not I restriction sites.
Results
The human AID 3’UTR contains sequences complementary
to miR-93 and miR-155
In light of the evidence supporting AID regulation by
miR-155 in mouse showing miR-155 regulates AID
translation and c-myc translocation [29,30], we asked if
human AID is regulated by similar microRNA interac-
tions. Computational analysis of the human AID 3’UTR
revealed a human miR-155 target site, consistent with
studies in mice [29,30]. To our surprise, we also found
pronounced complementarity between the AID 3’UTR
and miR-93 (Figure 1A). This miR-93 target site is
markedly more extensive than the majority of character-
ized miR::mRNA interactions containing only a single,
centrally located 4 bp mismatch. Strikingly, we find the
Figure 1 The AID 3’UTR.( A) Cartoon of AID 3’UTR miR target sites (TS) and internal (False) polyA (not to scale) (DNA sequence shown).
MicroRNA alignments are shown with corresponding binding affinities (kcal/mol). Vertical lines indicate complementary base pairing. Dotted
vertical lines indicate G:U base pairing. PolyA, AATAAA eukaryotic polyadenylation signal. Arrows indicate RT-PCR primer sets for confirmation of
expression. (B) RT-PCR to test expression of the AID 3’UTR miR-155 and miR-93 target site (TS) sequences in Ramos and MCF-7 cells.
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3’U T R( - 3 0 . 3k c a l / m o l e )t ob en e a r l yd o u b l et h a to f
miR-155 (-15.3 kcal/mole) (Figure 1A) suggesting a
strong post-transcriptional regulatory relationship.
Further analysis of the human AID 3’UTR revealed an
internal 20 nt stretch of adenosines (sufficient for cDNA
poly-T priming) separating the miR-155 and miR-93 tar-
get sites (Figure 1A). This false polyA is located ~1,000
nt 3’ of the AID stop codon and does not correspond to
the full length cDNA polyadenylation as: (1) it is not
preceded by the canonical 5’ AAUAAA poly adenylation
signal or other recognizable alternative poly adenylation
signal, and (2) the miR-93 target site is expressed in
both Ramos and MCF-7 cells (Figure 1B). Importantly,
examination of publically available EST datasets con-
firms this internal polyA stretch has repeatedly served
as an oligo-dT priming site for EST reverse transcriptase
leading to the improper annotation of a truncated AID
cDNA (for example see NCBI accessions GI:33871601
and GI:50496022). We conclude that the human AID
3’UTR contains miR-155 and miR-93 recognition sites,
which are separated by a 20 nucleotide adenosine repeat
upstream from the true polyA sequence.
MiR-93 and miR-155 interact with the AID 3’UTR to inhibit
its expression
The identification of miR-93 and miR-155 binding sites
in the 3’UTR of human AID strongly suggests post-tran-
scriptional regulatory interactions. Therefore, we next
asked if miR-93 and miR-155 were capable of regulating
the AID 3’UTR using standard luciferase reporter assays.
Three expression constructs incorporating an endogen-
ous human microRNA Alu promoter were created by
cloning the endogenous miR-517a genomic locus and
then replacing the miR-517a hairpin with the miR-93,
miR-155 and shLacZ hairpins (pAL-93, pAL-155, and
pAL-1 respectively)(Figure 2A), as described [32]. We
also generated 3’UTR reporter constructs to test AID::
miR regulatory interactions. These reporters (AID 3’LR
and Ctl 3’LR) produce Renilla luciferase transcripts
tailed with the AID 3’UTR and shLacZ target sequence
respectively (Figure 2B). Co-transfection of human
embryonic kidney (HEK293) cells with pAL-93 and AID
3’LR constructs resulted in ~80% knockdown of Renilla
luciferase intensity, whereas co-transfection of pAL-155
and AID 3’LR constructs resulted in ~60% knockdown
of Renilla luciferase intensity at a 4:1 transfection ratio
(Figure 2C). Similarly and as expected, co-transfection
of pAL-1 and Ctl 3’LR resulted in a reduction of Renilla
luciferase intensity with ~95% knockdown (Figure 2D).
In contrast and as expected, neither the co-transfection
of pAL-1 with AID 3’LR nor co-transfection of either
miR construct with Ctl 3’LR resulted in silencing (Figure
2C-D). To further ensure the repressions of AID 3’LR
by pAL-93 and pAL-155 were due to specific interac-
tions between miRs -93 and -155 and their proposed
target sites in the AID 3’UTR, we constructed two addi-
tional luciferase reporters whose 3’UTRs consisted of:
(1) the two target sites with intervening sequence
removed and (2) scrambled versions of the two target
sites with intervening sequence removed. Again, we
found co-transfection of human embryonic kidney
(HEK293) cells with pAL expression constructs and a
luciferase reporter containing intact miR target sites
resulted in significant repression of Renilla luciferase in
contrast to control transfections of scrambled miR tar-
get site reporters, which were not repressed (Additional
File 2, Figure S1). Therefore, miR-93 and miR-155
Figure 2 The AID 3’UTR is recognized by miRs -93 and -155.( A)
Diagrams of miR and siRNA expression vectors. 5’Alu corresponds to
a genomic fragment containing the miR-517a upstream Alu
promoter [32]. In pAL-1, shLacZ replaces the miR-517a hairpin. In
pALs-155 and -93, the pre-miR-155 and -93 hairpins replace the
miR-517a hairpin respectively. TTTT, RNA polymerase III termination
signal. (B) Diagrams of luciferase reporters. The AID 3’UTR luciferase
reporter (AID 3’LR) and control 3’UTR luciferase reporter (Ctl 3’LR)
were generated respectively by placing an AID 3’UTR sequence
containing both the miR-155 and miR-93 target sites and a specific
region of LacZ previously shown to be targeted by the pAL-1
shLacZ hairpin in a multiple cloning site in the Renilla luciferase
3’UTR [32]. HSV-TKp, herpes simplex virus thymidine kinase
promoter; SV40p, simian virus 40 promoter; FF Luc, firefly luciferase;
Ren Luc, Renilla luciferase; pA, poly(A). (C) AID 3’LR is specifically
repressed by both miR-93 and miR-155 in 293 transient
transfections. Luciferase assays (n = 4) of HEK293 lysates after
transfection of AID 3’LR and either pAL-1, pAL-155 or pAL-93.
Transfections were normalized to AID 3’LR alone. RLU, relative light
units. (D) Ctl 3’LR is specifically repressed by the ctl (pAL-1) in 293
transient transfections. Cotransfections done as in (C), except Ctl
3’LR replaced AID 3’LR.
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ficient to repress translation.
MiR-93 and miR-155 can repress endogenous AID
Interactions between miR-93, miR-155 and the AID
3’UTR within the context of our reporter assays (Figure
2C-D) strongly support the involvement of both miRs in
AID translational regulation. If so, we anticipated that if
miR-93 and/or miR-155 were present in AID expressing
cells they could suppress endogenous AID protein levels.
We therefore asked if miR-93 and miR-155 are present
in two cell lines known to express AID, Ramos and
MCF-7. Ramos is a B cell line that undergoes constitu-
tive AID-induced somatic hypermutation [33], and
MCF-7 is a breast carcinoma that misexpresses AID
[24]. Using standard RT-PCR analysis, we found miR
-93 and -155 transcripts are expressed in both cell lines
(Additional File 3, Figure S2), consistent with the ubi-
quitous expression documented for both of these miRs
[34]. In order to determine if endogenous AID can be
repressed by increased miR-93 and/or miR-155 expres-
sion, we introduced pAL miR over-expression plasmids
(Figure 2A) into MCF-7 cells [32]. Importantly, overex-
pression of miR-93, miR-155, or an AID-targeting
siRNA (shAID) in MCF-7 cells each reduced AID pro-
tein levels between 70 and 90%, whereas overexpression
of the pAL-1 control did not significantly alter AID
expression (Figure 3A). To ensure results were the con-
sequence of miR regulation, we confirmed the miR-93
repression of AID was dose-dependent (Additional File
4, Figure S3) and isolated total RNA from each of our
transfections to monitor AID mRNA levels by quantita-
tive PCR. Strikingly, while shAID transfection averaged
a 92% reduction of AID mRNA levels, neither pAL-93
nor pAL-155 transfection resulted in significant reduc-
tion of AID mRNA (Figure 3B) confirming that the
observed reductions in AID protein levels following
their transfections are mediated through translational
repression. To summarize, our results demonstrate that
the decreases in AID protein upon shAID transfection
were due to message degradation, whereas pAL-93 and
pAL-155 overexpression resulted in miR-mediated trans-
lational repression.
Endogenous miR-93 and miR-155 restrain AID protein
translation
Over-expression of miR-93 and miR-155 repressed the
expression of endogenous AID, supporting the model
that both miRs contribute to post-transcriptional reg-
ulation of AID. To be consistent with that hypothesis,
the loss of cellular miR-93 or miR-155 should result
in higher AID expression. Therefore, we depleted
miR-93 and miR-155 individually and then monitored
changes to AID protein levels by western blotting. To
achieve this, we constructed miR sponge transgenes
for miR-93 and miR-155 that function by competi-
tively inhibiting miR activity, as previously described
[35,36]. Our miR sponge transgenes produce RNAs
containing ~10 copies of the miR-93 or miR-155 AID
3’UTR complementary binding sites (Figure 4A). Indi-
vidual miR sponges or a negative control sponge
transgene were transiently transfected in MCF-7, and
relative AID protein levels measured by western.
MCF-7 cells expressing either miR-93 or miR-155
sponges showed clear dose-responsive increases in
AID protein levels, whereas control transfections did
not significantly alter AID protein expression (Figure
4B). To ensure these findings were the consequence of
restricted miR activity, we isolated total RNA from
each of our transfections and examined AID mRNA
levels by quantitative PCR. We found AID mRNA
levels largely unaffected byt r a n s f e c t i o no fs p o n g e
constructs further supporting endogenous roles for
these miRs in the restraint of AID translation (Figure
4C). We conclude that one function of endogenous
miR-93 and miR-155 expression is to restrict the
translation of AID mRNA.
Figure 3 MiR-93 and miR-155 can repress endogenous AID.( A)
Representative western demonstrating that transient transfection of
pAL-93, pAL-155 and shAID expression constructs repress
endogenous AID protein levels in MCF-7 cells. ShAID produces an
AID-targeting siRNA from a pAL-driven hairpin expression vector as
in 2A. Ctl, pAL-1 transfected; PCNA, Proliferating Cell Nuclear
Antigen load control. (B) Relative AID mRNA levels corresponding to
replicate transfections performed as in A (n = 3) as determined by
quantitative PCR.
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Model for AID repression
We have shown that miR-93 and miR-155 have the
capacity to repress AID translation and do so in the cel-
lular context. Overexpression of miR-93 or miR-155
reduced AID protein levels in MCF-7 breast cancer cells
(Figure 3A), whereas depletion of either endogenous
miR-93 or miR-155 resulted in increased AID transla-
tion (Figure 4) directly connecting miR expression with
changes in AID protein concentration. Based on our
f i n d i n g s ,w ep r o p o s eam o d e lf o rt h er e l a t i o n s h i p
between miRs -93 and -155 and AID regulation in main-
taining genomic integrity (Figure 5). In cellular circum-
stances where high levels of AID transcription exist
(such as antigen activated B cells or some established
cancers) AID mRNA levels overwhelm miR controls. In
these situations, endogenous miR-155 and miR-93 have
negligible influence on AID protein levels. In contrast,
miR-93 and miR-155 can greatly reduce the potential
for errant AID expression which protects the genome
from unwanted cytidine deamination and mutation by
restricting AID protein production (Figure 5). This may
be particularly important during S-phase when replica-
tion transiently denatures the DNA. Conspicuously,
miR-93 is intronically encoded within the minichromo-
some maintenance 7 (MCM7) gene, an essential replica-
tion licensing factor, and precursor miR-93 abundance
tracks with MCM7 expression levels [37,38]. It is there-
fore tempting to speculate that domestication of the
miR-93 microRNA along with the corresponding AID
3’UTR site occurred as a response to the selective pres-
sure for maintaining genome fidelity during replication.
Disruptions of miR-155 and miR-93 are associated with
AID-induced oncogenesis
Highlighting the importance of tightly controlled AID
expression, novel AID regulations continue to be
described. In 2008, miR-155 was identified as an impor-
tant repressor of AID translation in mice, and loss of
this regulation is lymphomagenic [29,30]. Our data now
demonstrate directly that expression of endogenous
miRs -93 and -155 represses AID translation in MCF-7
breast cancer cells. While a direct correlation between
miR-93 activity and AID-induced oncogenesis remains
to be described, miR-93 perturbations have been found
to enhance cell survival, possess oncogenic activities,
and augment tumor growth through regulating integrin-
b8, the tumor suppressor gene FUS1, the Cdk inhibitor
p21, and tumor protein 53-induced nuclear protein 1
(TP53INP1) [39-42]. Our results suggest that in addition
to these known oncogene regulations, loss of miR-93 (or
miR-155) may permit AID upregulation and mutator
phenotypes in non-B cell oncologies (e.g. breast, colon,
stomach and lung [21-24]). However, it is possible that
Figure 4 Endogenous miR-93 and miR-155 restrain AID protein
expression.( A) Diagram of miR sponge expression vector. TS
indicates an AID 3’UTR miR target site detailed in 1A. The miR-93
sponge produces a polyadenylated concatamer of 11 individual 93
TSs. Analogously designed, the miR-155 sponge contains 10
individual miR-155 TSs, and the ctl sponge contains 14 individual
shLacZ targets. CMVp, immediate early cytomegalovirus promoter;
SV40pA, simian virus 40 polyadenylation signal. (B) Representative
western demonstrating that transient transfection of MCF-7 cells
with the miR-93 or miR-155 sponges results in dose responsive
increases in AID protein levels as compared to control. Ctl, shLacZ
target site sponge transfected; PCNA, Proliferating Cell Nuclear
Antigen. (C) Relative AID mRNA levels corresponding to replicate
transfections performed as in B (n = 3) as determined by
quantitative PCR.
Figure 5 Model of miR-93 and miR-155 regulation of AID
mediated genomic instability. In normal cells, top, genome
stability is maintained by inhibition of AID translation by miR-93
and/or miR-155 when AID mRNA levels are low. Bottom, in antigen
activated B cells or when misregulated, levels of AID mRNA exceed
the capacity for miR translational repression. AID translation results
in AID protein levels that support Ig gene diversification,
mutagenesis and genome instability.
Borchert et al. BMC Cancer 2011, 11:347
http://www.biomedcentral.com/1471-2407/11/347
Page 6 of 9additional miR AID regulations may still be described,
and our research does not seek to eliminate other
potential regulators.
MicroRNA target sites obscured by repetitive element
insertions
Our identification of an extensive and uncharacterized
3’UTR for human AID reveals the presence of sequence
elements that may confound miR regulatory relation-
ships for other mRNAs. We find that the AID 3’UTR is
~1000 nt longer than previously annotated likely due to
mispriming from an internal stretch of 20 adenosines.
The full length AID 3’UTR contains a previously uni-
dentified regulatory sequence, an unusually pronounced
miR-93 complementarity, (Figure 1) conferring marked
repression to targeted transcripts (Figure 2 and Addi-
tional File 2, Figure S1). Clearly, this finding agrees with
recent suggestions that cryptic miR complementarities
may actually be quite common with nearly 50% of
human and mouse 3’UTRs likely extending well beyond
their annotated termini [43,44]. Since 3’UTRs contain
miR binding sites, our analysis of AID is consistent with
the notion that other miR posttranscriptional regulations
may have been overlooked because of truncated 3’UTR
annotations. This may be particularly pronounced in
humans as 5-10% of all human 3’UTRs contain at least
one Alu repeat, a common miR-associated retro-element
characterized by a central 10-40 nt adenosine linker
[32,45-51].
Conclusions
In the present study, two human microRNAs, miR-155
and miR-93, were each shown to repress the translation
of human AID through interactions with the AID 3’UTR
in the MCF-7 breast carcinoma cell line which aber-
rantly expresses AID. Together, our data suggest that
low-level errant AID expression and subsequent genome
d a m a g em a yb ep r e v e n t e dt h r o u g hp r o t e c t i v em i R - 9 3
and/or miR-155 regulation. In addition, our identifica-
tion of a miR-93 target site for AID located downstream
of an internal adenosine repeat highlights the possibility
that other miR regulations may have been overlooked
because of truncated 3’UTR annotations.
Additional material
Additional file 1: Table S1. Oligonucleotide master list. All
oligonucleotides were synthesized commercially (Fisher, Operon) at
either 25 or 100 nM scale. “pAL” refers to the human miR-517a Alu
promoter. “93” and “155” refer to human miRs. “TS” refers to a siRNA or
miR target site.
1, lowercase indicates imperfect antisense.
2, AID 3’LR was
generated using TS-155F and TS-93R.
3, designed previously [See
reference [32]].
Additional file 2: Figure S1. The AID 3’UTR is recognized by miRs
-93 and -155.( A) The AID 3’UTR recognition by miRs -93 and -155 is
specific. (A) Diagrams of luciferase reporters. The AID 3’UTR luciferase
reporter (TS Intact) and control 3’UTR luciferase reporter (TS Scram) were
generated respectively by placing the AID 3’UTR miR -93 and -155 target
sites (TS Intact)(with intervening sequences deleted) or an identical
sequence in which the target site nucleotides had been scrambled (TS
Scram) into a multiple cloning site in the Renilla luciferase 3’UTR [32].
HSV-TKp, herpes simplex virus thymidine kinase promoter; SV40p, simian
virus 40 promoter; FF Luc, firefly luciferase; Ren Luc, Renilla luciferase; pA,
poly(A); 155TS, miR-155 target site; 93TS, miR-93 target site; 155SC, miR-
155 target site scrambled; 93SC, miR-93 target site scrambled. (B)T S
Intact is specifically repressed by both miR-93 and miR-155 in 293
transient transfections. Luciferase assays (n = 9) of HEK293 lysates after
transfection of TS Intact and either pAL-1, pAL-155 or pAL-93.
Transfections were normalized to TS Intact alone. RLU, relative light units.
(C) TS Scram is unaffected by co-transfection of pAL-1, pAL-155 or pAL-
93 in 293 transient transfections. Cotransfections done as in B, except TS
Scram replaced TS Intact.
Additional file 3: Figure S2. MicroRNAs miR-93 and miR-155 are
widely expressed. RT-PCR of pre-miR template in three different cell
lines, HEK293 embryonic kidney cells, MCF-7 breast cancer line, and
Ramos Burkitt’s lymphoma line. (top) RT-PCR products of the miR-93
locus amplified from indicated cellular RNAs. m, miR-93; b, Beta actin
positive control; - Ctl, no template. (bottom) RT-PCR products of the
miR-155 locus amplified from indicated cellular RNAs. Annotations are
same as above except (m) denotes pre-miR-155 amplicon. PCR of source
RNAs failed, indicating above RT-PCRs templated from the generated
cDNA.
Additional file 4: Figure S3. MiR-93 represses endogenous AID in a
dose responsive manner.( A) Representative western demonstrating
that transient transfection of pAL-93 expression constructs repress
endogenous AID protein levels in MCF-7 cells in a dose responsive
manner. (B) Relative AID mRNA levels corresponding to replicate
transfections performed as in A (n = 2) determined by quantitative PCR.
List of abbreviations
AID: Activation Induced Deaminase; bp: base pair; ChIP: chromatin
immunoprecipitation; EST: expressed sequence tag; HEK: human embryonic
kidney; Ig: immunoglobulin; MCF-7: Michigan Cancer Foundation - 7 breast
cancer line; miR: microRNA; mRNA: messenger RNA; nt: nucleotide; pAL: Alu
promoter; TS: microRNA target site; UTR: mRNA untranslated region; 3’LR:
3’UTR luciferase reporter.
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